| Bioactivity | RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property[1]. |
| Target | EC50: 3 pM (GIPR), 5 pM (GLP Receptor) |
| In Vivo | RG7697 (3-30 nmol/kg，皮下注射，每天，共 7 天；或每两天一次，共 30 天) 促进胰岛素分泌和代谢，减少葡萄糖转移，并改善 C57BL/6 小鼠模型中饮食诱导的 2 型糖尿病和肥胖[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Sequence | Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Asp-Lys-Gln-Ala-Ala-{Aib}-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-{Lys(C16 acid)}-NH2 |
| Shortening | Y-{Aib}-EGTFTSDYSIYLDKQAA-{Aib}-EFVNWLLAGGPSSGAPPPS-{Lys(C16 acid)}-NH2 |
| Formula | C211H316N46O61 |
| Molar Mass | 4473.04 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schmitt C, et al., Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Oct;19(10):1436-1445. [2]. Finan B, et al., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. |